JP2004511547A - 尿失禁治療用の新規ｍ−アミノ−フェニルイミノ−イミダゾリジン誘導体 - Google Patents

尿失禁治療用の新規ｍ−アミノ−フェニルイミノ−イミダゾリジン誘導体 Download PDF

Info

Publication number: JP2004511547A
Authority: JP; Japan
Prior art keywords: dimethylamino; phen; methyl; chloro; iminoimidazolidine
Prior art date: 2000-10-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2002536060A

Other languages

English (en)

Japanese (ja)

Other versions

JP2004511547A5 (es

Inventor

エセール　フランツ

プーツェット　パスカーレ　アリーレ　ジャン　ジョゼー

喜多川　久人

酒井　兼司

村松　郁延

Original Assignee

ベーリンガー　インゲルハイム　ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング　ウント　コンパニー　コマンディトゲゼルシャフト

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-14

Filing date

2001-10-11

Publication date

2004-04-15

2001-10-11 Application filed by ベーリンガー　インゲルハイム　ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング　ウント　コンパニー　コマンディトゲゼルシャフト filed Critical ベーリンガー　インゲルハイム　ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング　ウント　コンパニー　コマンディトゲゼルシャフト

2004-04-15 Publication of JP2004511547A publication Critical patent/JP2004511547A/ja

2005-12-22 Publication of JP2004511547A5 publication Critical patent/JP2004511547A5/ja

Status Pending legal-status Critical Current

Links

206010046543 Urinary incontinence Diseases 0.000 title claims abstract description 18
QOBQHDFSJHQICB-UHFFFAOYSA-N 3-n-(4,5-dihydro-1h-imidazol-2-yl)benzene-1,3-diamine Chemical class NC1=CC=CC(NC=2NCCN=2)=C1 QOBQHDFSJHQICB-UHFFFAOYSA-N 0.000 title abstract description 7
238000000034 method Methods 0.000 claims abstract description 4
150000001875 compounds Chemical class 0.000 claims description 58
229910052794 bromium Inorganic materials 0.000 claims description 35
229910052731 fluorine Inorganic materials 0.000 claims description 27
229910052801 chlorine Inorganic materials 0.000 claims description 26
229910052739 hydrogen Inorganic materials 0.000 claims description 22
150000003839 salts Chemical class 0.000 claims description 18
238000004519 manufacturing process Methods 0.000 claims description 6
206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
DISXFZWKRTZTRI-UHFFFAOYSA-N 4,5-dihydro-1h-imidazol-2-amine Chemical compound NC1=NCCN1 DISXFZWKRTZTRI-UHFFFAOYSA-N 0.000 claims description 2
208000029162 bladder disease Diseases 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims description 2
208000026533 urinary bladder disease Diseases 0.000 claims description 2
MSYFITFSZJKRQJ-UHFFFAOYSA-N 4,5-dihydroimidazol-1-amine Chemical compound NN1CCN=C1 MSYFITFSZJKRQJ-UHFFFAOYSA-N 0.000 claims 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 6
239000008194 pharmaceutical composition Substances 0.000 abstract description 4
125000001424 substituent group Chemical group 0.000 abstract description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
239000000203 mixture Substances 0.000 description 14
239000000460 chlorine Substances 0.000 description 13
239000002904 solvent Substances 0.000 description 13
230000000694 effects Effects 0.000 description 12
239000000843 powder Substances 0.000 description 12
239000000126 substance Substances 0.000 description 11
229910052757 nitrogen Inorganic materials 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
239000002253 acid Substances 0.000 description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
239000000556 agonist Substances 0.000 description 7
239000008346 aqueous phase Substances 0.000 description 7
239000012074 organic phase Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
239000013078 crystal Substances 0.000 description 6
239000003480 eluent Substances 0.000 description 6
230000004060 metabolic process Effects 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
239000012458 free base Substances 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
NPLDFXDXQWVDGE-UHFFFAOYSA-N 4-bromo-2-methyl-3-nitroaniline Chemical compound CC1=C(N)C=CC(Br)=C1[N+]([O-])=O NPLDFXDXQWVDGE-UHFFFAOYSA-N 0.000 description 4
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical class ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 4
206010021639 Incontinence Diseases 0.000 description 4
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
239000005457 ice water Substances 0.000 description 4
150000002460 imidazoles Chemical class 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
FFDCCOGXCCFGQN-UHFFFAOYSA-N 2-chloro-3-n,3-n-dimethylbenzene-1,3-diamine Chemical compound CN(C)C1=CC=CC(N)=C1Cl FFDCCOGXCCFGQN-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229960002896 clonidine Drugs 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
125000001841 imino group Chemical group [H]N=* 0.000 description 3
229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
238000000746 purification Methods 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
238000005160 1H NMR spectroscopy Methods 0.000 description 2
SVODKDLZITYQHB-UHFFFAOYSA-N 2-chloro-n,n-dimethyl-3-nitroaniline Chemical compound CN(C)C1=CC=CC([N+]([O-])=O)=C1Cl SVODKDLZITYQHB-UHFFFAOYSA-N 0.000 description 2
KPVDRKNFFIVSCK-UHFFFAOYSA-N 4,5-dibromo-2-methyl-3-nitroaniline Chemical compound CC1=C(N)C=C(Br)C(Br)=C1[N+]([O-])=O KPVDRKNFFIVSCK-UHFFFAOYSA-N 0.000 description 2
ZFINLOWLCPMWHN-UHFFFAOYSA-N 4-bromo-1-n,1-n,2-trimethylbenzene-1,3-diamine Chemical compound CN(C)C1=CC=C(Br)C(N)=C1C ZFINLOWLCPMWHN-UHFFFAOYSA-N 0.000 description 2
IVHQWZQYWXTABA-UHFFFAOYSA-N 4-bromo-2-chloro-1-n,1-n-dimethylbenzene-1,3-diamine Chemical compound CN(C)C1=CC=C(Br)C(N)=C1Cl IVHQWZQYWXTABA-UHFFFAOYSA-N 0.000 description 2
GGCYXIDSVRFWGW-UHFFFAOYSA-N 4-bromo-n,n,2-trimethyl-3-nitroaniline Chemical compound CN(C)C1=CC=C(Br)C([N+]([O-])=O)=C1C GGCYXIDSVRFWGW-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
235000019502 Orange oil Nutrition 0.000 description 2
229910019213 POCl3 Inorganic materials 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000008602 contraction Effects 0.000 description 2
239000012043 crude product Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
NMYFXIITWKKOKY-UHFFFAOYSA-N n-(2-methyl-3-nitrophenyl)acetamide Chemical compound CC(=O)NC1=CC=CC([N+]([O-])=O)=C1C NMYFXIITWKKOKY-UHFFFAOYSA-N 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
239000010502 orange oil Substances 0.000 description 2
210000003903 pelvic floor Anatomy 0.000 description 2
239000012071 phase Substances 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl chloride Substances ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000007787 solid Substances 0.000 description 2
208000022170 stress incontinence Diseases 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
150000003512 tertiary amines Chemical class 0.000 description 2
-1 thiophene-pyrrole Chemical class 0.000 description 2
208000014001 urinary system disease Diseases 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
JJWACYUTERPMBM-UHFFFAOYSA-N 1-acetylimidazolidin-2-one Chemical compound CC(=O)N1CCNC1=O JJWACYUTERPMBM-UHFFFAOYSA-N 0.000 description 1
MLRVZFYXUZQSRU-UHFFFAOYSA-N 1-chlorohexane Chemical compound CCCCCCCl MLRVZFYXUZQSRU-UHFFFAOYSA-N 0.000 description 1
DJCMHDGLUZBVHN-UHFFFAOYSA-N 1-imidazolidin-1-ylethanone Chemical compound CC(=O)N1CCNC1 DJCMHDGLUZBVHN-UHFFFAOYSA-N 0.000 description 1
LFZMDHABIHTULU-UHFFFAOYSA-N 1-n-(4,5-dihydro-1h-imidazol-2-yl)-3-n,3-n-diethyl-2-methylbenzene-1,3-diamine Chemical compound CCN(CC)C1=CC=CC(N=C2NCCN2)=C1C LFZMDHABIHTULU-UHFFFAOYSA-N 0.000 description 1
RABBMOYULJIAFU-UHFFFAOYSA-N 1h-pyrrole;thiophene Chemical compound C=1C=CNC=1.C=1C=CSC=1 RABBMOYULJIAFU-UHFFFAOYSA-N 0.000 description 1
QESNXJCBZZLZGS-UHFFFAOYSA-N 2,4-dichloro-3-n-(4,5-dihydro-1h-imidazol-2-yl)benzene-1,3-diamine Chemical compound NC1=CC=C(Cl)C(N=C2NCCN2)=C1Cl QESNXJCBZZLZGS-UHFFFAOYSA-N 0.000 description 1
PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 description 1
OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
HFCFJYRLBAANKN-UHFFFAOYSA-N 2-methyl-3-nitroaniline Chemical compound CC1=C(N)C=CC=C1[N+]([O-])=O HFCFJYRLBAANKN-UHFFFAOYSA-N 0.000 description 1
YAVQHZNCRMTNLD-UHFFFAOYSA-N 2-phenyliminoimidazol-4-amine Chemical class N1=CC(N)=NC1=NC1=CC=CC=C1 YAVQHZNCRMTNLD-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
DLYHEPSOVBEVSM-UHFFFAOYSA-N 3-n-(4,5-dihydroimidazol-1-yl)benzene-1,3-diamine Chemical class NC1=CC=CC(NN2C=NCC2)=C1 DLYHEPSOVBEVSM-UHFFFAOYSA-N 0.000 description 1
BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
ADBAAWORPRBVBQ-UHFFFAOYSA-N 4,5-dibromo-1-n,1-n,2-trimethylbenzene-1,3-diamine Chemical compound CN(C)C1=CC(Br)=C(Br)C(N)=C1C ADBAAWORPRBVBQ-UHFFFAOYSA-N 0.000 description 1
KJLMIEZIVABUGA-UHFFFAOYSA-N 4,5-dibromo-n,n,2-trimethyl-3-nitroaniline Chemical compound CN(C)C1=CC(Br)=C(Br)C([N+]([O-])=O)=C1C KJLMIEZIVABUGA-UHFFFAOYSA-N 0.000 description 1
YYPQPWYCPPSSGY-UHFFFAOYSA-N 4-(1H-pyrazol-5-yl)imidazol-2-imine Chemical class N1N=C(C=C1)C1=NC(N=C1)=N YYPQPWYCPPSSGY-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
YOMKRLBTCUMZFX-UHFFFAOYSA-N CCN(CC)c1c(C)c(NC2=NCCN2)cc(Br)c1 Chemical compound CCN(CC)c1c(C)c(NC2=NCCN2)cc(Br)c1 YOMKRLBTCUMZFX-UHFFFAOYSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
241000700159 Rattus Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
229940030225 antihemorrhagics Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
229940073608 benzyl chloride Drugs 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
VFRCNXKYZVQYLX-UHFFFAOYSA-N deglymidodrine Chemical compound COC1=CC=C(OC)C(C(O)CN)=C1 VFRCNXKYZVQYLX-UHFFFAOYSA-N 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
239000002874 hemostatic agent Substances 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
150000003949 imides Chemical class 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000007774 longterm Effects 0.000 description 1
150000002668 lysine derivatives Chemical class 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229960001094 midodrine Drugs 0.000 description 1
CJDICMLSLYHRPT-UHFFFAOYSA-N n,n-dimethyl-3-nitroaniline Chemical compound CN(C)C1=CC=CC([N+]([O-])=O)=C1 CJDICMLSLYHRPT-UHFFFAOYSA-N 0.000 description 1
ZOMQJWXODXJRJK-UHFFFAOYSA-N n-(4,5-dibromo-2-methyl-3-nitrophenyl)acetamide Chemical compound CC(=O)NC1=CC(Br)=C(Br)C([N+]([O-])=O)=C1C ZOMQJWXODXJRJK-UHFFFAOYSA-N 0.000 description 1
JJJNSPRIMJIECZ-UHFFFAOYSA-N n-(4-bromo-2-methyl-3-nitrophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(Br)C([N+]([O-])=O)=C1C JJJNSPRIMJIECZ-UHFFFAOYSA-N 0.000 description 1
JCOPITWIWLFFPC-UHFFFAOYSA-N n-phenyl-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1NC1=CC=CC=C1 JCOPITWIWLFFPC-UHFFFAOYSA-N 0.000 description 1
YEPNQNIIERDOCM-UHFFFAOYSA-N n-phenylimidazol-2-imine Chemical class N1=CC=NC1=NC1=CC=CC=C1 YEPNQNIIERDOCM-UHFFFAOYSA-N 0.000 description 1
230000000422 nocturnal effect Effects 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000036407 pain Effects 0.000 description 1
230000000803 paradoxical effect Effects 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
229960001802 phenylephrine Drugs 0.000 description 1
ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical class NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 1
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
206010046494 urge incontinence Diseases 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

JP2002536060A 2000-10-14 2001-10-11 尿失禁治療用の新規ｍ−アミノ−フェニルイミノ−イミダゾリジン誘導体 Pending JP2004511547A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10051005		2000-10-14
PCT/EP2001/011764 WO2002032876A2 (de)	2000-10-14	2001-10-11	Neue m-amino-phenylimino-imidazolidin-derivate zur behandlung der harninkontinenz

Publications (2)

Publication Number	Publication Date
JP2004511547A true JP2004511547A (ja)	2004-04-15
JP2004511547A5 JP2004511547A5 (es)	2005-12-22

Family

ID=7659815

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2002536060A Pending JP2004511547A (ja)	2000-10-14	2001-10-11	尿失禁治療用の新規ｍ−アミノ−フェニルイミノ−イミダゾリジン誘導体

Country Status (23)

Country	Link
EP (1)	EP1328517A2 (es)
JP (1)	JP2004511547A (es)
KR (1)	KR20030046503A (es)
CN (1)	CN1471514A (es)
AR (1)	AR035923A1 (es)
AU (1)	AU2002215943A1 (es)
BG (1)	BG107711A (es)
BR (1)	BR0114603A (es)
CA (1)	CA2425563A1 (es)
CZ (1)	CZ20031333A3 (es)
DE (1)	DE10150312A1 (es)
EA (1)	EA200300460A1 (es)
EC (1)	ECSP034517A (es)
EE (1)	EE200300177A (es)
HU (1)	HUP0302245A3 (es)
IL (1)	IL155338A0 (es)
MX (1)	MXPA03003162A (es)
NO (1)	NO20031697L (es)
PL (1)	PL361359A1 (es)
SK (1)	SK4342003A3 (es)
WO (1)	WO2002032876A2 (es)
YU (1)	YU28203A (es)
ZA (1)	ZA200302345B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4168086B1 (ja) *	2008-04-16	2008-10-22	国立大学法人福井大学	イミダゾリン誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2806811A1 (de) *	1978-02-17	1979-08-23	Boehringer Sohn Ingelheim	Neue substituierte 2-phenylimino- imidazolidine, deren saeureadditionssalze, diese enthaltene arzneimittel und verfahren zur herstellung derselben
CA1201066A (en) *	1981-11-20	1986-02-25	Alcon Laboratories, Inc.	N-¬3,5-dichloro-4-(2-imidazolidinylideneamino)- phenyl\|-acetamide solutions for lowering intraocular pressure
DE19514579A1 (de) *	1995-04-20	1996-10-24	Boehringer Ingelheim Kg	Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz

2001
- 2001-10-11 YU YU28203A patent/YU28203A/sh unknown
- 2001-10-11 EE EEP200300177A patent/EE200300177A/xx unknown
- 2001-10-11 SK SK434-2003A patent/SK4342003A3/sk not_active Application Discontinuation
- 2001-10-11 JP JP2002536060A patent/JP2004511547A/ja active Pending
- 2001-10-11 CN CNA018170870A patent/CN1471514A/zh active Pending
- 2001-10-11 AU AU2002215943A patent/AU2002215943A1/en not_active Abandoned
- 2001-10-11 EP EP01987747A patent/EP1328517A2/de not_active Withdrawn
- 2001-10-11 CA CA002425563A patent/CA2425563A1/en not_active Abandoned
- 2001-10-11 BR BR0114603-3A patent/BR0114603A/pt not_active IP Right Cessation
- 2001-10-11 PL PL01361359A patent/PL361359A1/xx not_active Application Discontinuation
- 2001-10-11 WO PCT/EP2001/011764 patent/WO2002032876A2/de not_active Ceased
- 2001-10-11 HU HU0302245A patent/HUP0302245A3/hu unknown
- 2001-10-11 CZ CZ20031333A patent/CZ20031333A3/cs unknown
- 2001-10-11 IL IL15533801A patent/IL155338A0/xx unknown
- 2001-10-11 EA EA200300460A patent/EA200300460A1/ru unknown
- 2001-10-11 DE DE10150312A patent/DE10150312A1/de not_active Withdrawn
- 2001-10-11 MX MXPA03003162A patent/MXPA03003162A/es unknown
- 2001-10-11 KR KR10-2003-7005143A patent/KR20030046503A/ko not_active Withdrawn
- 2001-10-12 AR ARP010104787A patent/AR035923A1/es not_active Application Discontinuation
2003
- 2003-03-17 EC EC2003004517A patent/ECSP034517A/es unknown
- 2003-03-26 ZA ZA200302345A patent/ZA200302345B/en unknown
- 2003-04-08 BG BG107711A patent/BG107711A/xx unknown
- 2003-04-11 NO NO20031697A patent/NO20031697L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2002032876A3 (de)	2002-07-18
EP1328517A2 (de)	2003-07-23
KR20030046503A (ko)	2003-06-12
IL155338A0 (en)	2003-11-23
ECSP034517A (es)	2003-04-25
NO20031697D0 (no)	2003-04-11
MXPA03003162A (es)	2004-12-06
CZ20031333A3 (cs)	2003-08-13
BG107711A (bg)	2004-02-27
DE10150312A1 (de)	2002-07-04
PL361359A1 (en)	2004-10-04
HUP0302245A3 (en)	2004-01-28
WO2002032876A2 (de)	2002-04-25
AU2002215943A1 (en)	2002-04-29
CA2425563A1 (en)	2002-04-25
CN1471514A (zh)	2004-01-28
HUP0302245A2 (hu)	2003-10-28
EA200300460A1 (ru)	2004-02-26
EE200300177A (et)	2003-08-15
AR035923A1 (es)	2004-07-28
BR0114603A (pt)	2003-10-14
SK4342003A3 (en)	2003-10-07
YU28203A (sh)	2006-05-25
NO20031697L (no)	2003-05-26
ZA200302345B (en)	2004-04-23

Publication	Publication Date	Title
US4532331A (en)	1985-07-30	1-Benzyl-2-aminomethyl imidazole derivatives
PL166214B1 (pl)	1995-04-28	Sposób wytwarzania nowych pochodnych indolu PL PL PL PL PL PL PL
PL195000B1 (pl)	2007-07-31	Pochodne imidazopirydyny, sposób ich wytwarzania, środek farmaceutyczny, zastosowanie tych pochodnych i związki pośrednie
PL135749B1 (en)	1985-12-31	Method of obtaining novel imidazolilophenylamidines
US4835154A (en)	1989-05-30	1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors
JP3094384B2 (ja)	2000-10-03	臨床医学で使用されるヒスタミン受容体ｈ３の新規な拮抗作用化合物と、その受容体の拮抗物質として作用する医薬組成物と、その製造方法
US4719223A (en)	1988-01-12	Imidazolethiol dopamine-beta-hydroxylase inhibitors
SK138993A3 (en)	1994-11-09	Amidoalkyl - and imidoalkylpiperazines
US6602897B2 (en)	2003-08-05	m-Amino-phenylimino-imidazolidine derivatives for treating urinary incontinence
JP2004511547A (ja)	2004-04-15	尿失禁治療用の新規ｍ−アミノ−フェニルイミノ−イミダゾリジン誘導体
JP4168086B1 (ja)	2008-10-22	イミダゾリン誘導体
JP4567889B2 (ja)	2010-10-20	（（アミノイミノメチル）アミノ）アルカンカルボキシアミドおよび治療におけるその適用
US4267193A (en)	1981-05-12	N-substituted-4-(polyfluoro-2-hydroxy-2-propyl)anilines and compounds related thereto
JP2004517963A (ja)	2004-06-17	尿失禁治療用の新規なアルキル−フェニルイミノイミダゾリジン誘導体
US20020169193A1 (en)	2002-11-14	Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence
JP3265083B2 (ja)	2002-03-11	２−［２−（置換アミノ）ベンジルチオ］−５，６，７，８−テトラヒドロ−４（３ｈ）−キナゾリノン誘導体
CA2696314C (en)	2016-01-19	Therapeutic compounds
US4772723A (en)	1988-09-20	Dopamine β-hydroxylase inhibitors
US4863944A (en)	1989-09-05	Dopamine-β-hydroxylase inhibitors
US4873357A (en)	1989-10-10	Trifluoro acetyl-cyano-aniline intermediates for dopamine-βhydroxylase inhibitors
US5616604A (en)	1997-04-01	Aminopyrrolizinone analogues for anti-inflammation and analgesia (II)
HK1060568A (en)	2004-08-13	Novel m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence
ITMI20060836A1 (it)	2007-10-28	Composto 4-ammino-2,6-dimetilfenolico, un procedimento per prepararlo e composizione farmaceutica che lo comprende.
JPH0739423B2 (ja)	1995-05-01	ピリミドベンゾチアジン誘導体を含む抗炎症剤

Legal Events

Date	Code	Title	Description
2004-10-12	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041008
2004-10-12	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041008
2008-06-17	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080616
2008-06-20	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080618
2008-11-11	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081110